Prestige Brands Expects OTC Assets Will Shake Loose From M&A Activity

“If you looked at it based on history,” consolidation has created opportunities to acquire OTC brands, says Prestige Brands CEO Matthew Mannelly. The firm’s interest in adding brands is “stronger than ever,” he adds.

Prestige Brands Holdings Inc. head Matthew Mannelly looks at recent pharma industry mergers and sees not only industry consolidation, but also the likelihood of some consumer health care properties becoming the firm’s next acquisition targets.

Prestige Brands was the No. 6 OTC drug firm in North America with $1 billion sales for 2013 when including...

More from United States

More from North America